← Back to Search

Other

Cabiralizumab for Cancer (ADVISE Trial)

Phase 1
Waitlist Available
Led By Jason J. Luke, MD, FACP
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights

ADVISE Trial Summary

This trial is testing different combinations of immunotherapy to see which is most effective in treating solid tumors. The best treatment will be chosen based on how the tumor responds to various immunotherapy drugs.

ADVISE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with qualified tumor biopsy specimen at baseline
Secondary outcome measures
Number of Adverse Events (AEs)
Number of Adverse Events(AEs) leadind to discontinutaion
Number of Deaths
+4 more

ADVISE Trial Design

5Treatment groups
Experimental Treatment
Group I: Arm GExperimental Treatment2 Interventions
Combination therapy determined by biomarker assessment
Group II: Arm FExperimental Treatment2 Interventions
Combination therapy determined by biomarker assessment
Group III: Arm DExperimental Treatment2 Interventions
Combination therapy determined by biomarker assessment
Group IV: Arm CExperimental Treatment2 Interventions
Combination therapy determined by biomarker assessment
Group V: Arm BExperimental Treatment2 Interventions
Combination therapy determined by biomarker assessment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IDO1 Inhibitor
2018
Completed Phase 1
~20
Nivolumab
2014
Completed Phase 3
~4750
Relatlimab
2018
Completed Phase 2
~1120
Cabiralizumab
2018
Completed Phase 2
~620
Ipilimumab
2014
Completed Phase 3
~2620
Radiation Therapy
2017
Completed Phase 3
~7250

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,641 Previous Clinical Trials
4,130,044 Total Patients Enrolled
Jason J. Luke, MD, FACPPrincipal InvestigatorThe University of Pittsburgh Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
2018. "An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03335540.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top